ECSP099441A - Nuevos intermediarios y procesos útiles en la preparación de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona - Google Patents
Nuevos intermediarios y procesos útiles en la preparación de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanonaInfo
- Publication number
- ECSP099441A ECSP099441A EC2009009441A ECSP099441A ECSP099441A EC SP099441 A ECSP099441 A EC SP099441A EC 2009009441 A EC2009009441 A EC 2009009441A EC SP099441 A ECSP099441 A EC SP099441A EC SP099441 A ECSP099441 A EC SP099441A
- Authority
- EC
- Ecuador
- Prior art keywords
- piridin
- chlorophenyl
- pyridin
- bis
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a nuevos compuestos, benzoato de (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-il-vinil)piridin-3-il]metanona, y toluato de (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-il-vinil)piridin-3-il]metanono, los cuales son intermediarios útiles para la preparación del compuesto de Fórmula I:(I)La presente invención además se refiere a nuevos procesos para preparar un compuesto cristalino, el cual es {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1H-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona, Forma IV.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87085106P | 2006-12-20 | 2006-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP099441A true ECSP099441A (es) | 2009-07-31 |
Family
ID=39273082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2009009441A ECSP099441A (es) | 2006-12-20 | 2009-06-17 | Nuevos intermediarios y procesos útiles en la preparación de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona |
Country Status (22)
Country | Link |
---|---|
US (4) | US8772496B2 (es) |
EP (1) | EP2121610B1 (es) |
JP (1) | JP5443168B2 (es) |
KR (1) | KR20090081028A (es) |
CN (1) | CN101568523A (es) |
AU (1) | AU2007337255A1 (es) |
BR (1) | BRPI0721069A2 (es) |
CA (1) | CA2671770C (es) |
DK (1) | DK2121610T3 (es) |
EA (1) | EA200970604A1 (es) |
EC (1) | ECSP099441A (es) |
ES (1) | ES2471990T3 (es) |
HR (1) | HRP20140613T1 (es) |
IL (1) | IL198775B (es) |
MX (1) | MX2009006636A (es) |
NO (1) | NO20092370L (es) |
PL (1) | PL2121610T3 (es) |
PT (1) | PT2121610E (es) |
RS (1) | RS53386B (es) |
SI (1) | SI2121610T1 (es) |
WO (1) | WO2008079600A1 (es) |
ZA (1) | ZA200903578B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2121610T1 (sl) * | 2006-12-20 | 2014-08-29 | Eli Lilly & Company | Nove vmesne spojine in postopek, ki je uporaben pri pripravi (2-(1-(3,5-bistrifluorometil-benzil)-5-piridin-4-il-1h-(1,2,3)triazol- 4-il)-piridin-3-il)-(2-klorofenil)-metanona |
US10098859B2 (en) | 2012-09-05 | 2018-10-16 | Amri Ssci, Llc | Cocrystals of p-coumaric acid |
MX2017011279A (es) | 2015-03-04 | 2018-01-25 | Vanda Pharmaceuticals Inc | Metodo de tratamiento con tradipitant. |
WO2017031215A1 (en) * | 2015-08-17 | 2017-02-23 | Eli Lilly And Company | Process development of a pyridine-containing nk-1 receptor antagonist |
MX2020002852A (es) | 2017-09-13 | 2020-07-22 | Vanda Pharmaceuticals Inc | Tratamiento mejorado de dermatitis atopica con tradipitant. |
CN111343981A (zh) * | 2017-11-17 | 2020-06-26 | 万达制药公司 | 使用川地匹坦治疗胃肠疾病的方法 |
US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
US20220096449A1 (en) | 2018-12-03 | 2022-03-31 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
EP4125811A1 (en) * | 2020-03-26 | 2023-02-08 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
WO2023019084A1 (en) | 2021-08-12 | 2023-02-16 | Vanda Pharmaceuticals Inc. | Treatment of gastric accommodation with tradipitant |
WO2024138040A1 (en) | 2022-12-21 | 2024-06-27 | Vanda Pharmaceuticals Inc. | Methods of treatment with tradipitant |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60318697T2 (de) | 2002-04-26 | 2009-01-08 | Eli Lilly And Co., Indianapolis | Triazolderivate als tachykininrezeptor-antagonisten |
PT1675846E (pt) * | 2003-10-24 | 2010-04-20 | Lilly Co Eli | Novas formas cristalinas de {2-[1-(3,5-bis-trifluorometilbenzil)-5- iridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona |
WO2006083711A1 (en) * | 2005-02-01 | 2006-08-10 | Eli Lilly And Company | Tachykinin receptor antagonists |
SI2121610T1 (sl) * | 2006-12-20 | 2014-08-29 | Eli Lilly & Company | Nove vmesne spojine in postopek, ki je uporaben pri pripravi (2-(1-(3,5-bistrifluorometil-benzil)-5-piridin-4-il-1h-(1,2,3)triazol- 4-il)-piridin-3-il)-(2-klorofenil)-metanona |
-
2007
- 2007-12-04 SI SI200731483T patent/SI2121610T1/sl unknown
- 2007-12-04 EP EP07865137.9A patent/EP2121610B1/en active Active
- 2007-12-04 WO PCT/US2007/086319 patent/WO2008079600A1/en active Application Filing
- 2007-12-04 BR BRPI0721069-8A patent/BRPI0721069A2/pt not_active Application Discontinuation
- 2007-12-04 US US12/515,794 patent/US8772496B2/en active Active
- 2007-12-04 KR KR1020097012894A patent/KR20090081028A/ko not_active Application Discontinuation
- 2007-12-04 JP JP2009543027A patent/JP5443168B2/ja active Active
- 2007-12-04 MX MX2009006636A patent/MX2009006636A/es active IP Right Grant
- 2007-12-04 ES ES07865137.9T patent/ES2471990T3/es active Active
- 2007-12-04 PL PL07865137T patent/PL2121610T3/pl unknown
- 2007-12-04 AU AU2007337255A patent/AU2007337255A1/en not_active Abandoned
- 2007-12-04 PT PT78651379T patent/PT2121610E/pt unknown
- 2007-12-04 CN CNA2007800466993A patent/CN101568523A/zh active Pending
- 2007-12-04 EA EA200970604A patent/EA200970604A1/ru unknown
- 2007-12-04 RS RS20140349A patent/RS53386B/en unknown
- 2007-12-04 CA CA2671770A patent/CA2671770C/en active Active
- 2007-12-04 DK DK07865137.9T patent/DK2121610T3/da active
-
2009
- 2009-05-14 IL IL198775A patent/IL198775B/en active IP Right Grant
- 2009-05-22 ZA ZA200903578A patent/ZA200903578B/xx unknown
- 2009-06-17 EC EC2009009441A patent/ECSP099441A/es unknown
- 2009-06-22 NO NO20092370A patent/NO20092370L/no not_active Application Discontinuation
-
2014
- 2014-03-27 US US14/227,857 patent/US20140206877A1/en not_active Abandoned
- 2014-06-27 HR HRP20140613TT patent/HRP20140613T1/hr unknown
-
2015
- 2015-11-10 US US14/937,051 patent/US9708291B2/en active Active
-
2017
- 2017-06-15 US US15/623,550 patent/US10035787B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9708291B2 (en) | 2017-07-18 |
MX2009006636A (es) | 2009-06-30 |
CA2671770C (en) | 2015-09-15 |
US20160060250A1 (en) | 2016-03-03 |
US20100056795A1 (en) | 2010-03-04 |
EP2121610A1 (en) | 2009-11-25 |
RS53386B (en) | 2014-10-31 |
SI2121610T1 (sl) | 2014-08-29 |
US20140206877A1 (en) | 2014-07-24 |
KR20090081028A (ko) | 2009-07-27 |
JP2010513546A (ja) | 2010-04-30 |
CN101568523A (zh) | 2009-10-28 |
ZA200903578B (en) | 2010-07-28 |
BRPI0721069A2 (pt) | 2014-02-04 |
US10035787B2 (en) | 2018-07-31 |
US20170283394A1 (en) | 2017-10-05 |
ES2471990T3 (es) | 2014-06-27 |
JP5443168B2 (ja) | 2014-03-19 |
IL198775B (en) | 2018-08-30 |
PL2121610T3 (pl) | 2014-09-30 |
EA200970604A1 (ru) | 2009-10-30 |
WO2008079600A1 (en) | 2008-07-03 |
AU2007337255A1 (en) | 2008-07-03 |
CA2671770A1 (en) | 2008-07-03 |
NO20092370L (no) | 2009-09-16 |
PT2121610E (pt) | 2014-06-25 |
EP2121610B1 (en) | 2014-04-02 |
US8772496B2 (en) | 2014-07-08 |
DK2121610T3 (da) | 2014-06-30 |
IL198775A0 (en) | 2010-02-17 |
HRP20140613T1 (hr) | 2014-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP099441A (es) | Nuevos intermediarios y procesos útiles en la preparación de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona | |
AR121612A2 (es) | Inhibidores de glucosilceramida sintasa | |
NO20084783L (no) | Syntese av acylaminoalkenylenamider nyttige som substans P antagonister | |
HK1165954A1 (en) | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | |
ECSP099818A (es) | Procesos para la preparacion de pirazoles | |
NI201100049A (es) | Compuestos orgánicos. | |
PE20091493A1 (es) | Inhibidores de quinasa de pirrolopirazina | |
PE20151752A1 (es) | Amidas heterociclicas como inhibidores de cinasas | |
AR070395A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il- amina | |
PE20141380A1 (es) | Imidazopiridazinas como inhibidores de quinasa akt | |
PE20131153A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
WO2009065919A3 (de) | Organische verbindungen | |
WO2009065920A3 (de) | Verbindungen | |
MX347562B (es) | Derivados fungicidas de 3-fenil[(heterociclilmetoxi)imino]metil}-1 ,2,4-oxadiazol-5(4h)-ona sustituidos en 4. | |
DOP2011000113A (es) | Pirazolilaminopiridinas como inhibidores de fak | |
MY150778A (en) | Fused heterocyclic compound | |
WO2009065922A3 (de) | Organische verbindungen | |
EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии | |
MY156233A (en) | Disubstituted tetrahydrofuranyl compounds as antagonists of the bradykinin b1 receptor | |
NZ597916A (en) | Benzoquinolizinium salt derivatives as anticancer agents | |
RS54012B1 (en) | UNITS USED FOR CHK1 INHIBITION | |
UY31824A (es) | Nuevos compuestos | |
AR052174A1 (es) | Sulfonamido - macrociclos y sus sales como inhibidoras de tie2, composicion farmaceutica que comprende estos compuestos, metodo de prepararlos y su uso | |
CU20100252A7 (es) | Derivados de dibenzotiazepina | |
EA201001252A1 (ru) | Способ получения производных 3,6-дигидро-1,3,5-триазина |